Merck and Moderna reported late-stage results in August for a personalized mRNA cancer vaccine, with data indicating the approach slowed the return and spread of melanoma when added to existing therapy. The findings push mRNA cancer vaccines closer to broader development across additional tumor types. The coverage also spotlights the field-wide uncertainty over which cancers are most likely to respond and whether mRNA platform features can consistently drive durable immune control beyond melanoma. For biotech developers, the update reinforces near-term differentiation opportunities in antigen selection, dosing schedules, and combination strategies—especially as real-world sequencing of similar programs becomes more competitive.